Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Otenaproxesul pulled as Arthritis drug.

<< Previous

Bullboard Posts

Next >>

Comment by Nick80on Oct 14, 2021 7:31pm

238 Views

Post# 34007391

RE:RE:RE:RE:RE:RE:Otenaproxesul pulled as Arthritis drug.

A good question, I have to answer myself every day since the unexpected findings of the AME study. Why did I not just take the profit or later on digestible loss and see how things pan out, for now I will monitor and sell my position if there is not any material news within the next 3 month justifying me holding the bag any longer...

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success